D.E. Shaw & Co
REPL icon

D.E. Shaw & Co’s Replimune Group REPL Stock Holding History

D.E. Shaw & Co’s Portfolio REPL Stock Details REPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.21M Buy
+200,000
New +$1.22M ﹤0.01% 3112

Other funds holding REPL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCI
Ridgeback Capital Investments Miami Beach, Florida $80.9M AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

D.E. Shaw & Co's REPL Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Replimune Group (REPL) stake by 23% in Q2 2026, selling an estimated $3.34M and leaving 1,789,964 shares worth $19.8M. The position accounts for 0.01% of the portfolio, ranked #1286.

D.E. Shaw & Co first reported a position in REPL in Q3 2020 and has held it in 19 quarters since. The position peaked at $25M in Q4 2025. 199 funds tracked by Wall St. Rank hold REPL as of Q2 2026.

  • D.E. Shaw & Co held 1,789,964 shares of Replimune Group worth $19.8M as of Q2 2026.
  • D.E. Shaw & Co sold 546,564 Replimune Group shares in Q2 2026, an estimated $3.34M.
  • Replimune Group made up 0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #1286 holding.
  • D.E. Shaw & Co first reported a position in Replimune Group in Q3 2020 and has held it in 19 quarters since.
  • D.E. Shaw & Co's Replimune Group position peaked at $25M in Q4 2025.
  • 199 funds tracked by Wall St. Rank held Replimune Group as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.